COVID-19: beta-thalassemia subjects immunised?

Area of Science:

• Infectious Diseases
• Genetics
• Hematology

Background:

• COVID-19, caused by SARS-CoV-2, is a significant global health concern.
• Beta-thalassemia is a genetic disorder affecting hemoglobin beta-chain synthesis, with 1.5% of the global population being heterozygotes.
• A preprint study suggested SARS-CoV-2 may attack the hemoglobin beta-chain.

Purpose of the Study:

• To investigate a potential correlation between beta-thalassemia heterozygote prevalence and COVID-19 infection rates.
• To explore if genetic factors influence susceptibility or immunity to SARS-CoV-2.

Main Methods:

• Utilized multiple linear regression analysis.
• Examined COVID-19 infection evolution in three Italian regions (Puglia, Sardinia, Sicilia).
• Compared infection data with regional beta-thalassemia heterozygote prevalences.

Main Results:

• A statistically significant correlation was found between beta-thalassemia heterozygote prevalence and apparent immunity to COVID-19.
• Regional analysis indicated that higher prevalences of beta-thalassemia carriers were associated with lower COVID-19 infection rates.

Conclusions:

• Beta-thalassemia heterozygote status may confer a degree of natural immunity or resistance to COVID-19.
• These findings suggest a potential genetic protective factor against SARS-CoV-2 infection.
• Further research is essential to confirm these preliminary hypotheses and explore the underlying mechanisms.